CLVSQ has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CLVSQ has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-04-28), Clovis Oncology's current share price is $0.015. Clovis Oncology's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2022 was $1.33. Clovis Oncology's Cyclically Adjusted PB Ratio for today is 0.01.
The historical rank and industry rank for Clovis Oncology's Cyclically Adjusted PB Ratio or its related term are showing as below:
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.
Clovis Oncology's adjusted book value per share data for the three months ended in Sep. 2022 was $-2.886. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $1.33 for the trailing ten years ended in Sep. 2022.
The historical data trend for Clovis Oncology's Cyclically Adjusted PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clovis Oncology Quarterly Data | ||||||||||||||||||||
Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | |
Cyclically Adjusted PB Ratio | Get a 7-Day Free Trial | 0.81 | 0.83 | 0.84 | 0.85 | 0.90 |
For the Biotechnology subindustry, Clovis Oncology's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Clovis Oncology's Cyclically Adjusted PB Ratio distribution charts can be found below:
* The bar in red indicates where Clovis Oncology's Cyclically Adjusted PB Ratio falls into.
Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.
Clovis Oncology's Cyclically Adjusted PB Ratio for today is calculated as
Cyclically Adjusted PB Ratio | = | Share Price | / | Cyclically Adjusted Book per Share |
= | 0.015 | / | 1.33 | |
= | 0.01 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clovis Oncology's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2022 is calculated as:
For example, Clovis Oncology's adjusted Book Value per Share data for the three months ended in Sep. 2022 was:
Adj_Book | = | Book Value per Share | / | CPI of Sep. 2022 (Change) | * | Current CPI (Sep. 2022) |
= | -2.886 | / | 125.2265 | * | 125.2265 | |
= | -2.886 |
Current CPI (Sep. 2022) = 125.2265.
Clovis Oncology Quarterly Data
Book Value per Share | CPI | Adj_Book | |
201212 | 5.094 | 96.871 | 6.585 |
201303 | 4.567 | 98.209 | 5.823 |
201306 | 12.032 | 98.518 | 15.294 |
201309 | 11.452 | 98.790 | 14.517 |
201312 | 14.688 | 98.326 | 18.706 |
201403 | 13.945 | 99.695 | 17.516 |
201406 | 13.002 | 100.560 | 16.191 |
201409 | 11.432 | 100.428 | 14.255 |
201412 | 9.760 | 99.070 | 12.337 |
201503 | 7.415 | 99.621 | 9.321 |
201506 | 5.847 | 100.684 | 7.272 |
201509 | 10.823 | 100.392 | 13.500 |
201512 | 7.838 | 99.792 | 9.836 |
201603 | 6.065 | 100.470 | 7.559 |
201606 | 2.931 | 101.688 | 3.609 |
201609 | 1.478 | 101.861 | 1.817 |
201612 | -0.094 | 101.863 | -0.116 |
201703 | 3.891 | 102.862 | 4.737 |
201706 | 7.039 | 103.349 | 8.529 |
201709 | 6.106 | 104.136 | 7.343 |
201712 | 7.271 | 104.011 | 8.754 |
201803 | 6.040 | 105.290 | 7.184 |
201806 | 5.934 | 106.317 | 6.989 |
201809 | 4.433 | 106.507 | 5.212 |
201812 | 2.774 | 105.998 | 3.277 |
201903 | 1.412 | 107.251 | 1.649 |
201906 | -0.564 | 108.070 | -0.654 |
201909 | -1.596 | 108.329 | -1.845 |
201912 | -3.171 | 108.420 | -3.663 |
202003 | -1.728 | 108.902 | -1.987 |
202006 | -1.104 | 108.767 | -1.271 |
202009 | -1.850 | 109.815 | -2.110 |
202012 | -1.531 | 109.897 | -1.745 |
202103 | -2.114 | 111.754 | -2.369 |
202106 | -1.748 | 114.631 | -1.910 |
202109 | -1.762 | 115.734 | -1.907 |
202112 | -2.160 | 117.630 | -2.300 |
202203 | -2.108 | 121.301 | -2.176 |
202206 | -2.545 | 125.017 | -2.549 |
202209 | -2.886 | 125.227 | -2.886 |
Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.
Thank you for viewing the detailed overview of Clovis Oncology's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Thomas C. Harding | officer: See Remarks | 5500 FLATIRON PARKWAY, SUITE 100, BOULDER CO 80301 |
Gillian C Ivers-read | officer: See Remarks | C/O PHARMION CORPORATION, 2525 28TH STREET, BOULDER CO 80301 |
Lindsey Rolfe | officer: See remarks | C/O CLOVIS ONCOLOGY, INC., 499 ILLINOIS STREET, SUITE 200, SAN FRANCISCO CA 94158 |
Daniel W Muehl | officer: See remarks | 5 BILLERICA PARK, 101 BILLERICA AVE, NORTH BILLERCA MA 01862 |
Paul Edward Gross | officer: See Remarks | 5500 FLATIRON PARKWAY, SUITE 100, BOULDER CO 80302 |
Ronit Simantov | director | 1988 CHAPEL STREET, NEW HAVEN CT 06515 |
James C Blair | director | 5880 PACIFIC CENTER BLVD, SAN DIEGO CA 92121-4204 |
Patrick J Mahaffy | director, officer: President and CEO | C/O CLOVIS ONCOLOGY, INC., 5500 FLATIRON PARKWAY, SUITE 100, BOULDER CO 80301 |
Thorlef Spickschen | director | TRAUBENWEG 25, 64342 SEEHEIN-JUGENHEIM 2M 00000 |
Richard A. Fair | director | C/O BELLICUM PHARMACEUTICALS, INC., 2130 W. HOLCOMBE BLVD., STE. 800, HOUSTON TX 77030 |
Robert Azelby | director | 307 WESTLAKE AVE. NORTH, STE 300, SEATTLE WA 98109 |
Hooks Corwin Dale | officer: See remarks | C/O CLOVIS ONCOLOGY, INC., 5500 FLATIRON PARKWAY, BOULDER CO 80301 |
Paul H Klingenstein | director | 428 UNIVERSITY AVE, C/O ACCEL PARTNERS, PALO ALTO CA 94301 |
Ginger L Graham | director | AMYLIN PHARMACEUTICALS, INC., 885 ARAPAHOE AVENUE, BOULDER CO 80302 |
Brian G Atwood | director | ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104 |
From GuruFocus
By PRNewswire PRNewswire • 07-15-2022
By Business Wire Business Wire • 04-08-2022
By Business Wire Business Wire • 10-20-2021
By Business Wire Business Wire • 03-16-2022
By Business Wire Business Wire • 07-12-2021
By Business Wire Business Wire • 10-07-2021
By Business Wire Business Wire • 10-17-2022
By Barry Cohen • 08-30-2021
By Business Wire Business Wire • 08-24-2021